| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/NDT/GFG296 |
| P698 | PubMed publication ID | 12937223 |
| P50 | author | Masafumi Fukagawa | Q56997226 |
| P2093 | author name string | Naoshi Fukushima | |
| Michinori Hirata | |||
| Hiroyuki Ohkawa | |||
| Koichi Endo | |||
| Kyoko Katsumata | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 1770-1776 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. | |
| P478 | volume | 18 |
| Q28568245 | A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia |
| Q37276108 | A rat model of chronic kidney disease-mineral bone disorder |
| Q34683694 | Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study. |
| Q46436528 | Challenges in the therapy of secondary hyperparathyroidism |
| Q46470848 | Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats |
| Q80540597 | Differential effects of vitamin D receptor activators on vascular calcification in uremic rats |
| Q36712981 | Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease |
| Q37831804 | Experimental models of renal disease and the cardiovascular system. |
| Q33862710 | Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals |
| Q46631810 | Maxacalcitol is a possible less phosphatemic vitamin D analog |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q36947028 | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease |
| Q46568744 | Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism |
| Q90631576 | Research Models for Studying Vascular Calcification |
| Q46823232 | Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. |
| Q64079731 | Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease |
| Q36930927 | Vascular calcification and arterial stiffness in chronic kidney disease: implications and management |
| Q36554786 | Vascular calcification and renal osteodystrophy relationship in chronic kidney disease |
| Q37230788 | Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels |
| Q42092825 | Vitamin D and kidney disease |
| Q38152318 | Vitamin D and the cardiovascular system: an overview of the recent literature. |
| Q37892311 | Vitamin D and vascular calcification in chronic kidney disease |
| Q24240439 | Vitamin D compounds for people with chronic kidney disease not requiring dialysis |
| Q24240582 | Vitamin D compounds for people with chronic kidney disease requiring dialysis |
| Q36947025 | Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies |
Search more.